Melanoma Clinical Trial
Official title:
In Vivo Reflectance Confocal Microscopy for Pigmented Lesion Diagnosis: A Multi-center Study
The purpose of this study is to image pigmented skin lesions suspicious for melanoma with an
imaging technology called in vivo reflectance confocal microscopy. This technology uses low
intensity laser to image below the surface of the skin. The confocal images of the
suspicious skin lesion will be examined. The goal of this study is to compare the results of
the confocal image examination to the pathologic diagnosis of the skin lesion.
The technique being evaluated in this study uses reflectance confocal microscopy in vivo.
The term "in vivo" means in/on a living subject. In this study you will be the living
subject and the confocal microscope will be placed on your skin to look at your skin lesion.
The confocal microscope uses a weak laser light and a sophisticated lens to image the
individual cells that make up the skin. Your lesion will be photographed with high
resolution photography.
Patients will be imaged with the VivaScope 1500 reflectance confocal microscope during a
single patient visit. The lesion will be photographed with high resolution photography and a
high resolution dermoscopic device.
The lesion will then be prepared for RCM imaging. A skin contact device consisting of a
metal ring and window will be applied to the skin surrounding the lesion of interest with a
disposable medical grade adhesive. A wetting solution will be placed onto the skin. The
wetting solutions include a high index oil such as a clear cosmetic oil or mineral oil. A
wetting solution such as ultrasound gel will also be placed on the lens of the microscope.
Application of these agents diminishes artifacts caused by light scattering at the skin
surface. RCM images of the lesion will be captured through the window/contact device using
the Vivascope 1500 reflectance confocal microscope provided by Lucid, Inc. Two types of
images will be collected, mosaics and stacks. Mosaics are 12x12 confocal images that are
optically combined or "stitched" together to create a seamless representation of a 6mm x 6mm
total area at specific depths within the skin. Stacks are 0.5mm x 0.5mm confocal images
taken at 5 micron intervals from the keratin layer to the superficial dermis. Mosaics and
stacks will be acquired for the skin lesion. The total estimated imaging time for a patient
in this study is about 10 minutes for each lesion. More than one lesion may be imaged per
patient.
After the imaging is complete, the lesion will be biopsied. All lesion images will be saved
on a network server for later review and analysis. All imaging will be completed by trained
research staff familiar with confocal imaging.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|